GSK asks for results from Exelixis cancer drug

08/23/2007 | Bloomberg

GlaxoSmithKline has requested preliminary study results from Exelixis for the experimental cancer drug XL880. Exelixis could receive a $70 million milestone payment if GSK continues to develop the drug, one analyst said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX